Bio-Techne Corp splits its revenue into 4 lines in its filings. The largest line in fiscal 2026, which ended Jun 30, 2026 was Consumables at $985.1 million, 81% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
FY 2017
Jun 30, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1,215
|
1,220
|
1,159
|
1,137
|
1,106
|
931
|
739
|
714
|
643
|
563
|
| Consumables |
985
+1.3%
share 81.1%
|
972
+4.8%
share 79.7%
|
928
+1.1%
share 80.1%
|
918
+3.0%
share 80.7%
|
891
+18.5%
share 80.6%
|
752
+24.8%
share 80.8%
|
603
+2.3%
share 81.6%
|
589
+10.1%
share 82.5%
|
535
share 83.2%
|
—
|
| Instruments |
111
-1.3%
share 9.1%
|
112
+3.5%
share 9.2%
|
108
-3.4%
share 9.3%
|
112
-7.2%
share 9.9%
|
121
+28.8%
share 10.9%
|
94
+31.2%
share 10.1%
|
71
+5.8%
share 9.7%
|
68
+9.3%
share 9.5%
|
62
share 9.6%
|
—
|
| Services |
94
-15.5%
share 7.8%
|
112
+12.4%
share 9.1%
|
99
+15.7%
share 8.6%
|
86
+19.2%
share 7.5%
|
72
+8.4%
share 6.5%
|
66
+39.9%
share 7.1%
|
47
+24.7%
share 6.4%
|
38
+11.5%
share 5.3%
|
34
share 5.3%
|
—
|
| Royalty |
25
+5.5%
share 2.1%
|
24
+1.5%
share 1.9%
|
23
+10.6%
share 2.0%
|
21
-4.0%
share 1.9%
|
22
+16.6%
share 2.0%
|
19
+10.0%
share 2.0%
|
17
-11.9%
share 2.3%
|
19
+57.6%
share 2.7%
|
12
share 1.9%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TECH (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- MN
- Headquarters
- Minneapolis, MN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 842023
- Former names
- TECHNE CORP /MN/ (until Oct 28, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.